Form D · Pharmaceuticals

Metacrine, Inc.

San Diego, CA · CIK 0001634379

Offering snapshot reported Jun 20, 2018 · SEC filing

Reported sold
$65M
Offering amount: $65M
Investors reported
26
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 5, 2018
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 20, 2018Initial$65,000,000No comparison26SEC filing
Dec 13, 2017Initial$22,000,000No comparison7SEC filing
Nov 9, 2016Amendment$37,766,644$25,616,649vs Oct 6, 201520SEC filing
Oct 6, 2015Amendment$12,149,995$5,299,995vs Apr 13, 201518SEC filing
Apr 13, 2015Initial$6,850,000No comparison5SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-314940

Source: Form D, filed Jun 20, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Robert Adelman Director
Kristina Burow Director
Ronald Evans Director
Carol Gallagher Director
Jackie Hernandez Executive
Richard Heyman Director
Neil Mc Donnell Director, Executive
Trisha Millican Executive
Patricia Millican Executive
Amir Nashat Director
Ken Song Director, Executive
Kenneth Song Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
3985 Sorrento Valley Blvd. Suite C
San Diego, CA, 92121